Literature DB >> 10956409

Decreased expression of p27 protein is associated with advanced tumor stage in hepatocellular carcinoma.

A Tannapfel1, D Grund, A Katalinic, D Uhlmann, F Köckerling, U Haugwitz, M Wasner, J Hauss, K Engeland, C Wittekind.   

Abstract

Reduced expression of the cyclin-dependent kinase inhibitor p27 has previously been correlated with fatal clinical outcome in some tumors, including gastric, breast, and prostate cancers. For hepatocellular carcinoma, the findings are equivocal. In situ hybridization and immunohistochemistry were performed on a series of 203 curatively (R0) resected hepatocellular carcinomas and in corresponding non-cancerous liver tissue to detect p27. Patients receiving liver transplantation were excluded. The results were correlated with histopathological stage according to the UICC system, Edmondson grade, several other histopathological factors of possible prognostic significance, and finally patient survival. Whereas p27 mRNA was expressed homogeneously in all carcinomas examined, the p27 protein was found in various amounts. The labeling index of p27 protein was significantly lower in advanced stages of the disease (P < 0.001, chi(2) = 28.1). We observed decreased p27 protein in higher pT categories (P < 0.001, chi(2) = 24.7) and in multiple tumor nodules (P < 0.001, chi(2) = 9.3). Multivariate Cox survival analysis identified age, co-existing cirrhosis, and Edmondson grade as independent prognostic factors. We conclude that evaluation of p27 in hepatocellular carcinoma is useful to predict stage of disease and may have clinical significance, e.g., in predicting optimal therapeutic regimes. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10956409     DOI: 10.1002/1097-0215(20000720)89:4<350::aid-ijc6>3.0.co;2-3

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  25 in total

1.  MiR-222 overexpression promotes proliferation of human hepatocellular carcinoma HepG2 cells by downregulating p27.

Authors:  Yue-Feng Yang; Fei Wang; Jun-Jie Xiao; Yang Song; Ying-Ying Zhao; Yan Cao; Yi-Hua Bei; Chang-Qing Yang
Journal:  Int J Clin Exp Med       Date:  2014-04-15

Review 2.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

3.  MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability.

Authors:  C Wan; S Hou; R Ni; L Lv; Z Ding; X Huang; Q Hang; S He; Y Wang; C Cheng; X X Gu; G Xu; A Shen
Journal:  Oncogene       Date:  2013-12-16       Impact factor: 9.867

4.  MicroRNA-452 promotes tumorigenesis in hepatocellular carcinoma by targeting cyclin-dependent kinase inhibitor 1B.

Authors:  Qingliang Zheng; Qing Sheng; Caiying Jiang; Jianhong Shu; Jian Chen; Zuoming Nie; Zhengbing Lv; Yaozhou Zhang
Journal:  Mol Cell Biochem       Date:  2014-01-01       Impact factor: 3.396

5.  Cell proliferation, apoptosis and the related regulators p27, p53 expression in hepatocellular carcinoma.

Authors:  Zhao Jing; Ke-Jun Nan; Mei-Long Hu
Journal:  World J Gastroenterol       Date:  2005-04-07       Impact factor: 5.742

6.  Genetic polymorphisms in apoptosis-related genes and the prognosis of hepatocellular carcinoma.

Authors:  Guo-Peng Yu; Qian-Yi Xiao; Zhu-Qing Shi; Li-Sha Tang; Xiao-Pin Ma; Lu-Yao Zhang; Hai-Tao Chen; Wen-Jia Wang; Peng-Yin Zhang; Dong-Lin Ding; Hui-Xing Huang; Hexige Saiyin; Tao-Yang Chen; Pei-Xin Lu; Neng-Jin Wang; Hong-Jie Yu; Jie-Lin Sun; S Lilly Zheng; Jian-Feng Xu; Long Yu; De-Ke Jiang
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

Review 7.  p16 and p27 are functionally correlated during the progress of hepatocarcinogenesis.

Authors:  Yasunobu Matsuda; Takafumi Ichida
Journal:  Med Mol Morphol       Date:  2006-12-21       Impact factor: 2.309

8.  Expression and hypermethylation of p27 kip1 in hepatocarcinogenesis.

Authors:  Pu-Ping Lei; Zong-Ji Zhang; Li-Juan Shen; Jin-Yun Li; Qiong Zou; Hua-Xian Zhang
Journal:  World J Gastroenterol       Date:  2005-08-07       Impact factor: 5.742

Review 9.  Molecular mechanism underlying the functional loss of cyclindependent kinase inhibitors p16 and p27 in hepatocellular carcinoma.

Authors:  Yasunobu Matsuda
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

10.  Expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27Kip1 in hepatocellular carcinoma.

Authors:  Ke-Jun Nan; Zhao Jing; Ling Gong
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.